Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.

Kuo C, Kent PM, Logan AD, Tamulonis KB, Dalton KL, Batus M, Fernandez K, Mcfall RE.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26265. Epub 2016 Nov 5.

PMID:
28221727
2.

[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].

Yao Z, Yang S, Zhao Y, Yao S, Guo H, Liu Y.

Zhonghua Zhong Liu Za Zhi. 2014 Jul;36(7):541-5. Chinese.

PMID:
25327662
3.

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

Mora J, Cruz CO, Parareda A, de Torres C.

J Pediatr Hematol Oncol. 2009 Oct;31(10):723-9. doi: 10.1097/MPH.0b013e3181b2598c.

PMID:
19727011
4.

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.

Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, Olson TA, Wasilewski-Masker K, Alazraki A, Katzenstein HM.

Pediatr Blood Cancer. 2012 Nov;59(5):854-8. doi: 10.1002/pbc.24101. Epub 2012 Feb 2.

PMID:
22302783
5.

Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.

Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S, Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society of Medical Oncology (ASMO).

Asian Pac J Cancer Prev. 2012;13(2):463-7.

6.

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.

Lee EM, Rha SY, Lee J, Park KH, Ahn JH.

Cancer Chemother Pharmacol. 2012 Mar;69(3):635-42. doi: 10.1007/s00280-011-1742-5. Epub 2011 Sep 30.

PMID:
21959979
7.

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S, Grignani G, Tamburini A, Pollack SM, Picci P, Ferrari S.

BMC Cancer. 2016 Apr 20;16:280. doi: 10.1186/s12885-016-2312-3.

8.

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.

Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC.

Cancer. 2008 Jul 15;113(2):419-25. doi: 10.1002/cncr.23586.

9.

Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.

Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M.

Onkologie. 2008 Feb;31(1-2):11-6. doi: 10.1159/0000111756. Epub 2008 Jan 22.

PMID:
18268394
10.

Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.

Bay JO, Ray-Coquard I, Fayette J, Leyvraz S, Cherix S, Piperno-Neumann S, Chevreau C, Isambert N, Brain E, Emile G, Le Cesne A, Cioffi A, Kwiatkowski F, Coindre JM, Bui NB, Peyrade F, Penel N, Blay JY; Groupe Sarcome Français.

Int J Cancer. 2006 Aug 1;119(3):706-11. Erratum in: Int J Cancer. 2007 Jan 15;120(2):450. Penel, Nicolas [added].

11.

Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.

Song BS, Seo J, Kim DH, Lim JS, Yoo JY, Lee JA.

Pediatr Blood Cancer. 2014 Aug;61(8):1376-81. doi: 10.1002/pbc.25035. Epub 2014 Apr 1.

PMID:
24692087
12.

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.

Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L.

Ann Oncol. 2015 Oct;26(10):2125-32. doi: 10.1093/annonc/mdv310. Epub 2015 Jul 21. Erratum in: Ann Oncol. 2015 Dec;26(12):2507-8.

13.

Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.

Takahashi M, Komine K, Imai H, Okada Y, Saijo K, Takahashi M, Shirota H, Ohori H, Takahashi S, Chiba N, Mori T, Shimodaira H, Ishioka C.

PLoS One. 2017 May 10;12(5):e0176972. doi: 10.1371/journal.pone.0176972. eCollection 2017.

14.

Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.

Hingorani P, Eshun F, White-Collins A, Watanabe M.

J Pediatr Hematol Oncol. 2012 Oct;34(7):524-7.

PMID:
23007339
15.

Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.

Schmitt T, Kosely F, Wuchter P, Schmier JW, Ho AD, Egerer G.

Onkologie. 2013;36(7-8):415-20. doi: 10.1159/000353564. Epub 2013 Jul 8.

PMID:
23921760
16.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML.

J Clin Oncol. 2007 Jul 1;25(19):2755-63. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17602081
17.

Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.

Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y.

Jpn J Clin Oncol. 2012 May;42(5):427-31. doi: 10.1093/jjco/hys030. Epub 2012 Mar 26.

PMID:
22450929
18.

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.

Hensley ML.

Curr Opin Oncol. 2010 Jul;22(4):356-61. doi: 10.1097/CCO.0b013e32833aafef. Review.

PMID:
20520541
19.

Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.

Verschraegen CF, Arias-Pulido H, Lee SJ, Movva S, Cerilli LA, Eberhardt S, Schmit B, Quinn R, Muller CY, Rabinowitz I, Purdy M, Snyder D, Bocklage T.

Ann Oncol. 2012 Mar;23(3):785-90. doi: 10.1093/annonc/mdr299. Epub 2011 Jul 11.

PMID:
21746804
20.

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.

Yoon JH, Kwon MM, Park HJ, Park SY, Lim KY, Joo J, Park BK.

BMC Cancer. 2014 Aug 28;14:622. doi: 10.1186/1471-2407-14-622.

Supplemental Content

Support Center